These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 19888503)
1. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis]. Quartuccio L; Salvin S; Saracco M; Lombardi S; Fabris M; Mansutti E; Maset M; Pellerito S; De Vita S Reumatismo; 2009; 61(3):182-6. PubMed ID: 19888503 [TBL] [Abstract][Full Text] [Related]
2. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202 [TBL] [Abstract][Full Text] [Related]
3. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052 [TBL] [Abstract][Full Text] [Related]
4. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227 [TBL] [Abstract][Full Text] [Related]
5. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731 [TBL] [Abstract][Full Text] [Related]
6. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451 [TBL] [Abstract][Full Text] [Related]
7. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM; Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM; J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201 [TBL] [Abstract][Full Text] [Related]
9. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Gardette A; Ottaviani S; Tubach F; Roy C; Nicaise-Roland P; Palazzo E; Gill G; Meyer O; Dieudé P Joint Bone Spine; 2014 Oct; 81(5):416-20. PubMed ID: 24998790 [TBL] [Abstract][Full Text] [Related]
10. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Solau-Gervais E; Prudhomme C; Philippe P; Duhamel A; Dupont-Créteur C; Legrand JL; Houvenagel E; Flipo RM Joint Bone Spine; 2012 May; 79(3):281-4. PubMed ID: 21724444 [TBL] [Abstract][Full Text] [Related]
12. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Belmonte Serrano MA; Pincus T Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342 [No Abstract] [Full Text] [Related]
13. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003 [TBL] [Abstract][Full Text] [Related]
14. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966 [TBL] [Abstract][Full Text] [Related]
15. Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. Iannone F; Tampoia M; Giannini M; Lopalco G; Cantarini L; Villalta CD; Galeazzi M; Lapadula G Clin Exp Rheumatol; 2016; 34(3):424-9. PubMed ID: 26885600 [TBL] [Abstract][Full Text] [Related]
16. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374 [TBL] [Abstract][Full Text] [Related]
17. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493 [TBL] [Abstract][Full Text] [Related]
18. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers]. Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418 [TBL] [Abstract][Full Text] [Related]
19. Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis. Fabris M; Quartuccio L; Lombardi S; Benucci M; Manfredi M; Saracco M; Atzeni F; Morassi P; Cimmino MA; Pontarini E; Fabro C; Pellerito R; Sarzi-Puttini P; Cutolo M; Carletto A; Bambara LM; Fischetti F; Curcio F; Tonutti E; De Vita S Reumatismo; 2010; 62(4):253-8. PubMed ID: 21253618 [TBL] [Abstract][Full Text] [Related]
20. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R; J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]